Sudeep Pharma reported a 27.9% year-on-year increase in revenue from operations to ₹642.3 crore for the fiscal year 2026, compared to ₹501.9 crore in FY25. Profit after tax (PAT) for the year stood at ₹174.3 crore, up from ₹138.7 crore in the previous year, while EBITDA grew by 16.8% to ₹221.9 crore. The company disclosed these figures in its earnings call transcript submitted to the exchanges under Regulation 30 of the SEBI Listing Regulations, 2015.

For the fourth quarter of FY26, revenue from operations grew by 15.7% to ₹182.3 crore, with PAT for the quarter rising to ₹48.5 crore. EBITDA for Q4 FY26 stood at ₹62.6 crores, with a margin of 34.3%. The financial performance was achieved despite a volatile operating environment characterized by geopolitical uncertainties and inflation in raw material prices.

Financial Highlights

Operational and Strategic Updates

The company’s specialty ingredients vertical reported revenue growth of 62% to ₹280 crore, increasing its contribution to total revenue from 34% in FY25 to 44% in FY26. The pharma food and nutrition vertical grew by 10% during the year, contributing 56% to total revenue. Export business accounted for 60% of the total revenue mix.

Sudeep Pharma provided an update on its battery materials project at Dahej, Gujarat, confirming that Phase 1 capacity of 25,000 metric tons per year is on track for commissioning by April 2027. The company has engaged with 42 customers globally and has started receiving initial commercial purchase orders, including approximately 700 metric tons recently. The new greenfield manufacturing facility has completed internal production validation, and the customer approval process is underway.

Balance Sheet and Outlook

Working capital days increased to 213 days from 184 days, primarily due to a strategic increase in inventory to mitigate procurement risks and support customer commitments. The company’s net debt stood at ₹33.6 crore as of March 31, 2026, with a net debt-to-equity ratio of 0.04x. Management indicated a focus on normalizing the working capital cycle to 150–160 days within the current financial year.

Sudeep Pharma Limited has reported its audited consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 21, 2026, and subsequently published in Business Standard and Vadodara Samachar on May 22, 2026. The company's board recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. Additionally, the board appointed M/s. Chetan Gandhi & Associates as Cost Auditor and M/s H M Mehta & Associates as Secretarial Auditor for the financial year 2026-27.

Q4 Consolidated Financial Performance

For the fourth quarter ended March 31, 2026, Sudeep Pharma reported consolidated total income from operations of ₹18,876.34 lakhs, compared to ₹16,130.57 lakhs in the same period last year. Net profit after tax for the quarter stood at ₹4,853.82 lakhs, up from ₹4,418.57 lakhs year-on-year. Total comprehensive income for the quarter came in at ₹5,470.10 lakhs, compared to ₹4,336.86 lakhs in Q4 FY25. Earnings per share (basic and diluted) for the quarter were ₹4.38, against ₹4.07 in the corresponding prior-year period.

Full Year Consolidated Financial Highlights

For the full financial year ended March 31, 2026, Sudeep Pharma reported consolidated total income from operations of ₹67,084.34 lakhs, a significant increase from ₹51,132.83 lakhs in the previous year. Net profit after tax for the year rose to ₹17,428.47 lakhs from ₹13,872.92 lakhs, reflecting a year-on-year growth of approximately 26%. Total comprehensive income for the full year stood at ₹17,305.95 lakhs, compared to ₹13,709.41 lakhs in FY25. Equity share capital as at March 31, 2026 stood at ₹1,129.49 lakhs, while reserves (excluding revaluation reserve) were ₹87,204.31 lakhs. Annual earnings per share (basic and diluted) were ₹15.50, up from ₹12.79 in FY25. The company completed an Initial Public Offering (IPO) during the year, listing its shares on the NSE and BSE on November 28, 2025.

Standalone Financial Performance

On a standalone basis, total income from operations for Q4 FY26 was ₹8,978.62 lakhs, compared to ₹10,794.93 lakhs in Q4 FY25. Standalone net profit after tax for the quarter stood at ₹2,576.56 lakhs, against ₹3,313.56 lakhs in the year-ago period. For the full year, standalone total income from operations grew to ₹37,700.94 lakhs from ₹36,510.73 lakhs, while standalone net profit after tax rose to ₹10,758.07 lakhs from ₹9,574.77 lakhs.

Strategic Capacity Expansion for FY27

Sudeep Pharma has outlined an ambitious capacity expansion roadmap for FY27 across its key business segments. In the Pharma, Food, and Nutrition segment, the company is targeting a total capacity of 86,200 MT, supported by a 51,200 MT greenfield project currently underway. The Specialty Ingredients segment capacity is maintained at 37,500 MT, while Phase 1 of the Battery Materials facility — focused on Iron Phosphate production — is being launched with a starting capacity of 25,000 MT.

The following table summarises the planned capacity targets across segments:

The greenfield project at Nandesari has completed the Internal Validation and Qualification Process, with Customer Validation Trials currently ongoing. The groundbreaking ceremony for the Battery Materials Facility in Dahej was successfully conducted on January 23, 2026, with Phase 1 construction currently underway and expected to be completed by early CY27.